Tiziana Life Sciences PLC (LON:TILS – Get Free Report) shares passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 58.50 ($0.75) and traded as low as GBX 45 ($0.58). Tiziana Life Sciences shares last traded at GBX 58.50 ($0.75), with a volume of 297,127 shares traded.
Tiziana Life Sciences Price Performance
The stock has a fifty day moving average of GBX 58.50 and a 200-day moving average of GBX 58.50. The company has a quick ratio of 6.41, a current ratio of 6.54 and a debt-to-equity ratio of 2.36. The firm has a market capitalization of £113.85 million and a P/E ratio of -3.59.
Tiziana Life Sciences Company Profile
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma.
Further Reading
- Five stocks we like better than Tiziana Life Sciences
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Technology Stocks Explained: Here’s What to Know About Tech
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.